ICHGCP中英文对照分析和总结.docx

  1. 1、本文档共21页,可阅读全部内容。
  2. 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
ICH 三方协调指导原则 E6 ICH GCP 指导原则INTRODUCTION 前 言 Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. 临床试验管理规范(GCP)是设计、实施、记录和报告设计人类对象参加的试验国际性伦理和科学质量标准。遵循这一标准为保护对象的权利、安全性和健康,为与源于赫尔辛基宣言的原则保持一致以及临床试 验数据的可信性提供了公众保证。 The objective of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions. ICH-GCP 指导原则的目的是为欧盟、日本和美国提供统一的标准,以促进这些管理当局在其权限内相互接受临床数据。 The guideline was developed with consideration of the current good clinical practices of the European Union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the World Health Organization (WHO). 本指导原则的发展考虑了欧盟、日本、美国,以及澳大利亚、加拿大、北欧国家和世界卫生组织(WHO) 的现行 GCP。 This guideline should be followed when generating clinical trial data that are intended to be submitted to regulatory authorities. 在产生打算提交给管理当局的临床数据时应当遵循本指导原则。 The principles established in this guideline may also be applied to other clinical investigations that may have an impact on the safety and well-being of human subjects. 本指导原则中确立的原则也可应用于可能影响人类对象安全和健康的其他临床研究。 1. GLOSSARY 术语 Adverse Drug Reaction (ADR) 药品不良反应(ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase responses to a medicinal product means that a causal relationship between a medicinal

文档评论(0)

tianya189 + 关注
官方认证
内容提供者

该用户很懒,什么也没介绍

认证主体阳新县融易互联网技术工作室
IP属地上海
统一社会信用代码/组织机构代码
92420222MA4ELHM75D

1亿VIP精品文档

相关文档